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A comprehensive description of morbidity and mortality in
patients affected by mutations in genes encoding for signal
transducers of the RAS-MAPK cascade (RASopathies) was per-
formed in our study recently published in the International Journal
of Cardiology. Seven European cardiac centres participating to the
CArdiac Rasopathy NETwork (CARNET), collaborated in this mul-
ticentric, observational, retrospective data analysis and collection.
In this study, clinical records of 371 patients with confirmed
molecular diagnosis of RASopathy were reviewed. Cardiac defects,
crude mortality, survival rate of patients with 1) hypertrophic
cardiomyopathy (HCM) and age o2 years or young adults; 2)
individuals with Noonan syndrome and pulmonary stenosis car-
rying PTPN11 mutations; 3) biventricular obstruction and PTPN11
mutations; 4) Costello syndrome or cardiofaciocutaneous syn-
drome were analysed. Mortality was described as crude mortality,
cumulative survival and restricted estimated mean survival. In
particular, with this Data In Brief (DIB) paper, the authors aim to
report specific statistic highlights of the multivariable regression
analysis that was used to assess the impact of mutated genes on
number of interventions and overall prognosis.
& 2017 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specifications Tableubject area Clinical Cardiology, Genetics, Rare Diseases, Morbility and Mortality
ore specific sub-
ject areaRASopathies, congenital heart defects, Hypertrophic Cardiomyopathy, Costello
Syndrome, Noonan Syndrome, LEOPARD syndrome, cardiofaciocutaenous
Syndromeype of data Table, figures
ow data was
acquiredClinicians analysisata format Filtered and analyzed
xperimental
factorsMolecular diagnosis was performed through a combination of Sanger sequen-
cing and targeted resequencing directed to scan the entire coding sequence of
CBL, PTPN11, SOS1, KRAS, HRAS, NRAS, SHOC2, RAF1, BRAF, MAP2K1 and
MAP2K2 genes.xperimental
featuresAnalysis were retrospectively performed.
Tables report the correlation between genetic testing and outcomes of the
related research article.
No experimental features were used or applied to data collection and analysis.ata source
locationRome, Bologna, Padua, Turin, Genoa, Naples (Italy)
London (United Kingdom)ata accessibility Data is with this article and not in a public repository
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articleCardiac defects, morbidity and mortality in patients affected by RASopathies.
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Int J Cardiol. 2017 Oct 15;245:92-98. http://dx.doi.org/10.1016/j.ijcard.2017.07.
068. Epub 2017 Jul 21.Value of the data
 Rasopathy syndromes are a well known entity and specific genotype-cardiac phenotype correlation
have been established. Limited information is available on genotype, phenotype and clinical/sur-
gical cardiac outcomes in these patients, thus more data need to be collected and analysed.
 The large cohort recently published in the related research article provides specific information on
cardiac morbidity and mortality about RASopathies. In this study the authors demonstrated that
cardiac mortality is relatively uncommon in these disorders and that in specific subsets of patients,
risk factors for surgical mortality or sudden death can be observed.
 Statistical correlations reported in tables and figures of the present DIB paper focus in details on
genes description for each syndrome, genetic testing, mortality rate and surgical re-intervention.
 Defining the worse cardiac phenotype spectrum will be essential to target specific treatment
phenotype/gene/mutation-specific in patient affected with RASopathies. This knowledge also allow
to optimize the counselling for family and for patients affected by these genetic disorders.1. Data
Data shared consist in peculiar details and explanation of methods and techniques of the statistical
analysis of patients’ reports and overall data. Moreover, we have correlated patients and parameters
in the following figures and tables.
– Fig. 1: Patients characteristics and procedures are described in details in DIB, which is a detailed
analysis of the first part of Table 1 of the related research article;
– Table 1 shows the distribution of mutated disease genes by syndrome;
– In Fig. 2, multiple forest plots reports effect sizes and BCa 95% Cls of the adjusted regression
analyses. This figure refers to the re-intervention of patients, and to peculiar aspects of Fig. 1 of the
related research article;
– Additional supplementary tables: the relation between morbility and genetic mutation, syndromes
and cardiac defects is reported. Data were presented as median and range, mean7standard
deviation (SD), or percentages and CI, as appropriate. These supplementary tables better explain
some correlations observed in Fig. 1 of related research article.2. Experimental design, materials and methods
The cardiac defects that were taken into account in the analyses were selected based on the
clinical impact of each single defect on the natural history of disease [1]. HCM, PS, and AVC were
selected as principal cardiac defects. Although ASD, VSD and valve anomalies were relatively frequent
in the present study cohort, they were excluded from the statistical analysis due to poor clinical
impact (i.e. ASD) and/or to their frequent association with other major cardiac defects (e.g., mitral
valve anomalies and HCM). Therefore, although the frequency of every cardiac defects are described,
only HCM, PS, and AVC were investigated more thoroughly.
Fig. 1. Patient's characteristics and procedures.
Table 1
Distribution of the mutated disease genes by clinical diagnosis.
Gene (N,%) NS NSML CFCS CS Total
PTPN11 216 42 0 0 258
SOS1 44 0 0 0 44
BRAF 6 1 15 0 22
RAF1 17 2 0 0 19
SHOC2 9 0 0 0 9
HRAS 1 0 0 7 8
MAP2K1 0 0 5 0 5
MAP2K2 0 0 2 0 2
KRAS 2 0 0 0 2
CBL 1 0 0 0 1
NRAS 1 0 0 0 1
Total 297 45 22 7 371
G. Calcagni et al. / Data in Brief 16 (2018) 649–654652We investigated all relevant gene mutations present in our population, but given the rarity of most
genetic defects in RASophaties, we decided to focus on mutations of BRAF, PTPN11, RAF1 and SOS1.
Especially, when plotting the results of the analyses, we reported only the results relative to this
subset of genes in order to increase clarity and interpretability.
We performed a number of inferential analyses using multivariable regression models.
The models were chosen according to the type of dependent variable investigated.
Poisson regression was used to study the association between mutated genes and the number of
procedures received by each patient with a cardiac defect (interpreted as a count variable), adjusting
for sex, presence of PS, HCM, AVC or OHD, and natural logarithm of years of follow-up, to take into
account the length of the follow up for each subject. Through Poisson regression, we investigated the
association of each syndrome with the number of interventions, adjusting for sex, type of heart defect
and length of follow up (transformed as above), and association between presence of PS, HCM, AVC
and OHD, and the number of interventions, correcting for sex, gene, and length of follow up
(transformed as above).
Fig. 2. Forest plots reporting effect, size and BCa 95% Cls of the adjusted regression analysis.
G. Calcagni et al. / Data in Brief 16 (2018) 649–654 653Regression analyses were performed using a Bayesian regularization approach with a non-infor-
mative prior with a Cauchy distribution, which allows for more stable estimates in case of unbalanced
class distribution or perfect/quasi-perfect predictor-outcome separation, avoiding the production of
extreme estimates which are probable to be random fluctuation, therefore improving reproducibility
of results [2].
Kaplan-Meier (KM) curves were used to describe the incidental risk of intervention and mortality,
stratified by time, for each mutated gene, syndrome and heart defect; 95% confidence intervals (95%
CI) are shown for the cumulative survival KM plots. In the population of subjects with heart defects,
Cox proportional hazards models were used to assess the effect of having a mutated gene, a syndrome
or a specific heart defect on the risk of intervention, respectively adjusting for sex and heart defect,
sex and heart defect, sex and gene.
Variability of the estimates was assessed by applying a non-parametric bootstrap analysis with
5000 repetitions in order to be more robust in presence of non-normal distributions of the investi-
gated effects, which is a common situation when facing complex, multifactorial phenomena [3].
Standardized effect sizes (sES), defined as the ratio between mean and SD of the bootstrap dis-
tributions of the predictors, were reported to assess the inferential strength of each predictor on the
outcomes (the further from zero is the absolute value, the stronger is the effect).
Accuracy of the estimates is reported as bias-corrected and accelerated bootstrap 95% Confidence
Intervals (BCa 95% CIs) [4]. BCa 95% CIs and effect sizes have been exponentiated in order to be
interpreted as adjusted Odds Ratio (aOR) in case of logistic regressions, adjusted Incidence Rate Ratios
(aIRR) in case of Poisson regressions, and adjusted hazard ratios (aHR) when considering the Cox
model.
A relationship was considered significant when the BCa 95% CIs were either greater or smaller
than the null effect. For each analysis, we took into account only subjects for whom the considered
variables were present. The actual number of subjects that entered in each analysis is reported in each
table.
We purposely decided not to report p-values since we believe this statistic can lead to a superficial
if not mislead interpretation of research results [5, 6]. We believe that confidence intervals and effect
sizes report all the information necessary for the interpretation of regression results, since they
G. Calcagni et al. / Data in Brief 16 (2018) 649–654654provide both a measure of uncertainty (the length of the confidence interval) and a estimation of the
strength of the relationships (the effect sizes) between variables.
We also report the sES in order to provide a further synthetic statistic which join precision and
strength of an effect, giving an approximate degree of inferential importance without misleading
probabilistic implications. Many share our criticism of p value, therefore we decided to avoid using it
in this publication.Acknowledgements
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